Approved comparison material connected to this topic.
15 total recordsSource comparisons are presented without a generated winner.
The table below compares dosage ranges, pharmacokinetic profiles, and research applications across the three viable administration routes for SS-31 in preclinical models. Subcutaneous 1-5mg/kg 60-90 minutes 5-…
0.25mg/kg/hour × 4 hours (single infusion) Intravenous, one-time +3.1% LVEF, −5.2mL LVESV 8% (mostly infusion site reactions) Acute decompensated HF stabilisation Best for short-term functional improvement wit…
EMBRACE STEMI (2020) Acute myocardial infarction 0.25 mg/kg single dose within 6 hours of PCI Subcutaneous 20% reduction in infarct size at 30-day MRI vs placebo (p<0.01) First trial to demonstrate tissue salv…
Low-dose maintenance 0.25mg/kg Twice daily Subcutaneous ~85% 8-10 hours per dose Healthspan extension in young-to-middle-aged models Standard therapeutic 0.5-1mg/kg Aging mitochondrial dysfunction, cardiovascu…
Cardiac ischemia-reperfusion (animal) 0.5–1mg/kg Intravenous bolus Single dose or 3–7 days Infarct size, ejection fraction Lowest effective dose due to high cardiac cardiolipin density. IV ensures rapid tissue…
0.1 mg/kg 90 minutes Time to exhaustion +3.2% (not significant) Sedentary adults Insufficient dose for measurable mitochondrial protection during exercise 0.25 mg/kg 60 minutes VO2 efficiency at submaximal loa…
Cardiac ischemia-reperfusion models 1–3mg/kg Once daily or 30min pre-event 24–72 hours (infarct size reduction) Best evidence base. Multiple RCTs show cardiolipin stabilization prevents reperfusion injury more…
Most published SS-31 trials used subcutaneous injection, but early preclinical work tested intravenous bolus dosing. The pharmacokinetic difference is significant: IV administration produces peak plasma concen…
| Vial Size | Purity | Active Mass | Reconstitution Volume | Final Concentration | 2mg Dose Volume | Usable Doses (accounting for dead volume) | Professional Assessment ||—|—|—|—|—|—|—|| 5mg | 96% | 4.8mg | 2m…
Acute ischemia (cardiac, renal, CNS) 3–5mg/kg IV bolus Single dose pre-injury 40–60% reduction in tissue necrosis vs control Timing trumps dose. Administer 30–60 min before anticipated oxidative event Neurodeg…
Ischemia-Reperfusion Injury 0.25–1.0 mg/kg IV bolus or short infusion Single dose or 4-hour infusion Infarct size reduction of 30–40% at 0.5 mg/kg with no further benefit at higher doses Optimal dose is 0.5 mg…
Baseline mitochondrial aging studies (healthy models) 5–10mg weekly Once per week 8–12 weeks Standard protocol for examining age-related decline in ATP production and ROS management. Sufficient to saturate car…
Mitochondrial Disorder Support 0.25–0.3 Morning, fasted Barth syndrome, MELAS, chronic fatigue with confirmed mito dysfunction 4–8 weeks for measurable VO2 or lactate ratio changes Clinically validated. Lowest…
The following table compares dosing protocols from major published research categories, highlighting the body weight calculations, administration routes, and timing considerations that determine effective mito…
Subcutaneous bolus (once daily) 0.5–1mg/kg ~85% 3.5 hours 2–4 hours to peak Acute injury models, short-term studies Simplest administration but produces peak-trough fluctuation; acceptable for protocols under …